Literature DB >> 16940126

Activity of picolinic acid in combination with the antiprotozoal drug quinacrine against Mycobacterium avium complex.

Toshiaki Shimizu1, Haruaki Tomioka.   

Abstract

We studied the in vitro and in vivo antimicrobial activities of picolinic acid (PA) in combination with the antiprotozoal drug quinacrine against intramacrophage Mycobacterium avium complex (MAC). Quinacrine significantly potentiated the anti-MAC activity of PA, suggesting the usefulness of this combination in the clinical control of MAC infection.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16940126      PMCID： PMC1563513          DOI： 10.1128/AAC.01510-05

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

Review 1.  Present status and future prospects of chemotherapeutics for intractable infections due to Mycobacterium avium complex.

Authors:  Haruaki Tomioka
Journal:  Curr Drug Discov Technol       Date:  2004-12

Review 2.  Treatment of giardiasis.

Authors:  T B Gardner; D R Hill
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

3.  Conditional lethality of the diprotic weak bases chloroquine and quinacrine against Cryptococcus neoformans.

Authors:  T S Harrison; G E Griffin; S M Levitz
Journal:  J Infect Dis       Date:  2000-06-30       Impact factor: 5.226

4.  Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease.

Authors:  Luiz E Bermudez; Peter Kolonoski; Mary Petrofsky; Martin Wu; Clark B Inderlied; Lowell S Young
Journal:  J Infect Dis       Date:  2003-06-04       Impact factor: 5.226

5.  Macrophage control of mycobacterial growth induced by picolinic acid is dependent on host cell apoptosis.

Authors:  T F Pais; R Appelberg
Journal:  J Immunol       Date:  2000-01-01       Impact factor: 5.422

6.  [Effect of combined chemotherapy following the guidelines on treatment for Mycobacterium avium complex pulmonary disease].

Authors:  Yoshihiro Kobashi; Niro Okimoto; Toshiharu Matsushima; Eriko Shigetou; Toshihiko Kuraoka; Hiroyasu Takeyama; Ryousuke Eda; Shuichi Yano; Kanako Kobayashi; Takayuki Ohnishi; Kenichi Mori; Yoshio Ueda; Tomonori Moritaka; Kazutaka Nishimura; Takahiro Abe
Journal:  Kekkaku       Date:  2002-06

7.  Induction of Mycobacterium avium growth restriction and inhibition of phagosome-endosome interactions during macrophage activation and apoptosis induction by picolinic acid plus IFNgamma.

Authors:  Teresa F Pais; Rui Appelberg
Journal:  Microbiology       Date:  2004-05       Impact factor: 2.777

8.  Interstitial quinacrine activates a distinctive immune response effective for tumor immunotherapy.

Authors:  Julio Sotelo; Patricia Guevara; Benjamin Pineda; Claudia Diaz
Journal:  Surgery       Date:  2004-09       Impact factor: 3.982

9.  Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine.

Authors:  Esteban C Nannini; Michael Keating; Peter Binstock; George Samonis; Dimitrios P Kontoyiannis
Journal:  J Infect       Date:  2002-04       Impact factor: 6.072

10.  Characterization and quantitation of a zinc-binding ligand in human milk.

Authors:  G W Evans; P E Johnson
Journal:  Pediatr Res       Date:  1980-07       Impact factor: 3.756
View more
  3 in total

1.  The physiological action of picolinic Acid in the human brain.

Authors:  R S Grant; S E Coggan; G A Smythe
Journal:  Int J Tryptophan Res       Date:  2009-04-28

Review 2.  Tryptophan Metabolites Along the Microbiota-Gut-Brain Axis: An Interkingdom Communication System Influencing the Gut in Health and Disease.

Authors:  Annalisa Bosi; Davide Banfi; Michela Bistoletti; Cristina Giaroni; Andreina Baj
Journal:  Int J Tryptophan Res       Date:  2020-06-11

3.  Inhibiting Sialidase-Induced TGF-β1 Activation Attenuates Pulmonary Fibrosis in Mice.

Authors:  Tejas R Karhadkar; Thomas D Meek; Richard H Gomer
Journal:  J Pharmacol Exp Ther       Date:  2020-11-03       Impact factor: 4.030
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.